A malignant neuroendocrine neoplasm composed of cells containing secretory granules that stain positive for NSE and chromogranin. The neoplastic cells are often round and form clusters or trabecular s...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding neuroendocrine carcinoma is limited due to its relatively low prevalence and the complexity of its clinical features. As this condition affects fewer individuals, systematic clinical studies and comprehensive data collection have been challenging. Additionally, the lack of identified genetic factors and specific phenotypic characterization further complicates understanding and documenting this disease.
To navigate your care effectively, seek out an oncologist who specializes in neuroendocrine tumors, as they will have the expertise to manage your condition. Consider reaching out to The Healing Net Foundation for support and resources tailored to patients with neuroendocrine carcinoma. Additionally, participating in a patient registry or natural history study may provide valuable insights into your condition and contribute to broader research efforts. For genetic counseling, you can find a professional through the National Society of Genetic Counselors at findageneticcounselor.com.
There are several orphan drugs currently designated for neuroendocrine carcinoma, including 225Ac, an alpha-emitting radionuclide targeting the DLL3 receptor, and various bispecific monoclonal antibodies aimed at enhancing immune response against tumor cells. With 492 active clinical trials available, patients have opportunities to participate in cutting-edge research. For more information on ongoing studies, visit ClinicalTrials.gov and search for neuroendocrine carcinoma.
Actionable guidance for navigating care for neuroendocrine carcinoma
To navigate your care effectively, seek out an oncologist who specializes in neuroendocrine tumors, as they will have the expertise to manage your condition. Consider reaching out to The Healing Net Foundation for support and resources tailored to patients with neuroendocrine carcinoma. Additionally, participating in a patient registry or natural history study may provide valuable insights into your condition and contribute to broader research efforts. For genetic counseling, you can find a professional through the National Society of Genetic Counselors at findageneticcounselor.com.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the neuroendocrine carcinoma community
Helpful links for rare disease information and support
The documentation surrounding neuroendocrine carcinoma is limited due to its relatively low prevalence and the complexity of its clinical features. As this condition affects fewer individuals, systematic clinical studies and comprehensive data collection have been challenging. Additionally, the lack of identified genetic factors and specific phenotypic characterization further complicates understanding and documenting this disease.
To navigate your care effectively, seek out an oncologist who specializes in neuroendocrine tumors, as they will have the expertise to manage your condition. Consider reaching out to The Healing Net Foundation for support and resources tailored to patients with neuroendocrine carcinoma. Additionally, participating in a patient registry or natural history study may provide valuable insights into your condition and contribute to broader research efforts. For genetic counseling, you can find a professional through the National Society of Genetic Counselors at findageneticcounselor.com.
There are several orphan drugs currently designated for neuroendocrine carcinoma, including 225Ac, an alpha-emitting radionuclide targeting the DLL3 receptor, and various bispecific monoclonal antibodies aimed at enhancing immune response against tumor cells. With 492 active clinical trials available, patients have opportunities to participate in cutting-edge research. For more information on ongoing studies, visit ClinicalTrials.gov and search for neuroendocrine carcinoma.
Actionable guidance for navigating care for neuroendocrine carcinoma
To navigate your care effectively, seek out an oncologist who specializes in neuroendocrine tumors, as they will have the expertise to manage your condition. Consider reaching out to The Healing Net Foundation for support and resources tailored to patients with neuroendocrine carcinoma. Additionally, participating in a patient registry or natural history study may provide valuable insights into your condition and contribute to broader research efforts. For genetic counseling, you can find a professional through the National Society of Genetic Counselors at findageneticcounselor.com.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the neuroendocrine carcinoma community
Helpful links for rare disease information and support
The documentation surrounding neuroendocrine carcinoma is limited due to its relatively low prevalence and the complexity of its clinical features. As this condition affects fewer individuals, systematic clinical studies and comprehensive data collection have been challenging. Additionally, the lack of identified genetic factors and specific phenotypic characterization further complicates understanding and documenting this disease.
To navigate your care effectively, seek out an oncologist who specializes in neuroendocrine tumors, as they will have the expertise to manage your condition. Consider reaching out to The Healing Net Foundation for support and resources tailored to patients with neuroendocrine carcinoma. Additionally, participating in a patient registry or natural history study may provide valuable insights into your condition and contribute to broader research efforts. For genetic counseling, you can find a professional through the National Society of Genetic Counselors at findageneticcounselor.com.
There are several orphan drugs currently designated for neuroendocrine carcinoma, including 225Ac, an alpha-emitting radionuclide targeting the DLL3 receptor, and various bispecific monoclonal antibodies aimed at enhancing immune response against tumor cells. With 492 active clinical trials available, patients have opportunities to participate in cutting-edge research. For more information on ongoing studies, visit ClinicalTrials.gov and search for neuroendocrine carcinoma.
Actionable guidance for navigating care for neuroendocrine carcinoma
To navigate your care effectively, seek out an oncologist who specializes in neuroendocrine tumors, as they will have the expertise to manage your condition. Consider reaching out to The Healing Net Foundation for support and resources tailored to patients with neuroendocrine carcinoma. Additionally, participating in a patient registry or natural history study may provide valuable insights into your condition and contribute to broader research efforts. For genetic counseling, you can find a professional through the National Society of Genetic Counselors at findageneticcounselor.com.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the neuroendocrine carcinoma community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 5 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.